Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells
Abstract
:1. Introduction
2. Results and Discussion
2.1. Synthesis of NO•-Releasing COXIBs
2.2. COX Inhibition
2.3. LogDpH7.4, HPLC
2.4. NO•-Release
2.5. Effects on Sensitivity of Tumor Spheroids to External Beam (X-Ray) Irradiation and Lu-177
3. Experimental Section
3.1. Materials and Methods
3.2. Chemistry
3.2.1. General Synthetic Procedure A
3.2.2. General Synthetic Procedure B
3.2.3. General Synthetic Procedure C
3.2.4. General Synthetic Procedure D
3.3. Synthesis of N-Propionyl-Substituted Compounds
3.4. Determination of COX Inhibition
3.5. Determination of Lipophilicity
3.6. Fluorometric NO• Release Assay (Griess Assay)
3.7. Conversion in NO•-Assay Buffer followed by UPLC and HPLC-HRMS
3.8. Gene Expression Analysis
3.9. Spheroid Regrowth Assay
3.10. Statistical Analyses
4. Summary and Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Sample Availability
Appendix A. Details on NMR Analysis of Final Compounds
References
- Lenders, J.W.; Eisenhofer, G.; Mannelli, M.; Pacak, K. Phaeochromocytoma. Lancet 2005, 366, 665–675. [Google Scholar] [CrossRef]
- Salmenkivi, K.; Heikkilä, P.; Haglund, C.; Arola, J. Malignancy in Pheochromocytomas. Apmis 2004, 112, 551–559. [Google Scholar] [CrossRef] [PubMed]
- Kashfi, K.; Rigas, B. The Mechanism of Action of Nitric Oxide-Donating Aspirin. Biochem. Biophys. Res. Commun. 2007, 358, 1096. [Google Scholar] [CrossRef]
- Consalvi, S.; Poce, G.; Ragno, R.; Sabatino, M.; La Motta, C.; Sartini, S.; Calderone, V.; Martelli, A.; Ghelardini, C.; Mannelli, L.D.; et al. A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis. Chemmedchem 2016, 11, 1804–1811. [Google Scholar] [CrossRef] [Green Version]
- Ullrich, M.; Bergmann, R.; Peitzsch, M.; Zenker, E.F.; Cartellieri, M.; Bachmann, M.; Ehrhart-Bornstein, M.; Block, N.L.; Schally, A.V.; Eisenhofer, G.; et al. Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics 2016, 6, 650–665. [Google Scholar] [CrossRef] [PubMed]
- Kong, G.; Grozinsky-Glasberg, S.; Hofman, M.S.; Callahan, J.; Meirovitz, A.; Maimon, O.; Pattison, D.A.; Gross, D.J.; Hicks, R.J. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. J. Clin. Endocrinol. Metab. 2017, 102, 3278–3287. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Castinetti, F.; Kroiss, A.; Kumar, R.; Pacak, K.; Taieb, D. 15 YEARS OF PARAGANGLIOMA: Imaging and Imaging-Based Treatment of Pheochromocytoma and Paraganglioma. Endocr. Relat. Cancer 2015, 22, T135–T145. [Google Scholar] [CrossRef] [Green Version]
- Ullrich, M.; Liers, J.; Peitzsch, M.; Feldmann, A.; Bergmann, R.; Sommer, U.; Richter, S.; Bornstein, S.R.; Bachmann, M.; Eisenhofer, G.; et al. Strain-Specific Metastatic Phenotypes in Pheochromocytoma Allograft Mice. Endocr. Relat. Cancer 2018, 25, 993–1004. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ullrich, M.; Richter, S.; Seifert, V.; Hauser, S.; Calsina, B.; Martínez-Montes, Á.M.; ter Laak, M.; Ziegler, C.G.; Timmers, H.; Eisenhofer, G.; et al. Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. Cancers 2019, 11, 743. [Google Scholar] [CrossRef] [Green Version]
- Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition. Pharm. Rev. 2004, 56, 387–437. [Google Scholar] [CrossRef] [PubMed]
- Tandler, N.; Mosch, B.; Pietzsch, J. Protein and Non–Protein Biomarkers in Melanoma: A Critical Update. Amino Acids 2012, 43, 2203–2230. [Google Scholar] [CrossRef] [PubMed]
- Haase-Kohn, C.; Laube, M.; Donat, C.K.; Belter, B.; Pietzsch, J. CRISPR/Cas9 Mediated Knockout of Cyclooxygenase-2 Gene Inhibits Invasiveness in A2058 Melanoma Cells. Cells 2022, 11, 749. [Google Scholar] [CrossRef] [PubMed]
- Cheki, M.; Yahyapour, R.; Farhood, B.; Rezaeyan, A.; Shabeeb, D.; Amini, P.; Rezapoor, S.; Najafi, M. COX-2 in Radiotherapy: A Potential Target for Radioprotection and Radiosensitization. Curr. Mol. Pharm. 2018, 11, 173–183. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Dubois, R.N. Prostaglandins and Cancer. Gut 2006, 55, 115–122. [Google Scholar] [CrossRef]
- Aggarwal, B.B.; Gehlot, P. Inflammation and Cancer: How friendly is the relationship for cancer patients? Curr. Opin. Pharm. 2009, 9, 351–369. [Google Scholar] [CrossRef] [Green Version]
- Qian, S.H.; Huang, Y.Z.; Li, J.M.; Zhang, Y.C.; Zhang, B.; Jin, F. Synthesis and Anti–proliferative Activity of Indole-2-Amide Derivatives as Cyclooxygenase-2/5-lipoxygenase (COX-2/5-LOX) Dual Inhibitors. Chin. J. Org. Chem. 2021, 41, 1631–1638. [Google Scholar] [CrossRef]
- Cai, H.; Huang, X.J.; Xu, S.T.; Shen, H.; Zhang, P.F.; Huang, Y.; Jiang, J.Y.; Sun, Y.J.; Jiang, B.; Wu, X.M.; et al. Discovery of Novel Hybrids of Diaryl-1,2,4-Triazoles and Caffeic Acid as Dual Inhibitors of Cyclooxygenase-2 and 5-Lipoxygenase for Cancer Therapy. Eur. J. Med. Chem. 2016, 108, 89–103. [Google Scholar] [CrossRef]
- Magierowski, M.; Jasnos, K.; Drozdowicz, D.; Ptak-Belowska, A.; Flannigan, K.L.; Kwiecien, S.; Wallace, J.L.; Brzozowski, T. Hydrogen Sulfide (H2S)-Releasing Derivative of Naproxen Atb-346 Protects the Gastric Mucosa Compromised by Stress. A Comparative Study With Naproxen and Cyclooxygenase (COX)-2 Inhibitor. Gastroenterology 2014, 146, S505. [Google Scholar] [CrossRef]
- Farag, D.B.; Farag, N.A.; Esmat, A.; Abuelezz, S.A.; Ibrahim, E.A.S.; El Ella, D.A.A. Synthesis, 3D Pharmacophore, QSAR and Docking Studies of Novel Quinazoline Derivatives with Nitric Oxide Release Moiety as Preferential COX-2 Inhibitors. MedChemComm 2015, 6, 283–299. [Google Scholar] [CrossRef]
- Chowdhury, M.A.; Abdellatif, K.R.A.; Dong, Y.; Yu, G.; Huang, Z.; Rahman, M.; Das, D.; Velázquez, C.A.; Suresh, M.R.; Knaus, E.E. Celecoxib Analogs Possessing a N-(4-nitrooxybutyl)Piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-Tetrahydropyridin-4-yl nitric Oxide Donor Moiety: Synthesis, Biological Evaluation and Nitric oxide Release Studies. Bioorg. Med. Chem. Lett. 2010, 20, 1324–1329. [Google Scholar] [CrossRef]
- Anzini, M.; Di Capua, A.; Valenti, S.; Brogi, S.; Rovini, M.; Giuliani, G.; Cappelli, A.; Vomero, S.; Chiasserini, L.; Sega, A.; et al. Novel Analgesic/Anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. J. Med. Chem. 2013, 56, 3191–3206. [Google Scholar] [CrossRef] [PubMed]
- Rao, B.N.; Muthuppalaniappan, M.; Dinavahi, S.S.; Viswanadha, S.; Bagul, C.; Srinivas, K.; Vakkalanka, S.K.V.S.; Atcha, K.R.; Kamal, A. Synthesis of 1,5-Diarylpyrazoles as Potential COX-2 Inhibitors with Nitric Oxide Releasing Ability. Lett. Drug. Des. Discov. 2013, 10, 594–603. [Google Scholar] [CrossRef]
- Soliman, W.M.; Abdellatif, K.R.A.; Knaus, E.E. Design, Synthesis, Biological Evaluation, and Nitric-Oxide Release Studies of a Novel Series of Celecoxib Prodrugs Possessing a Nitric-Oxide Donor Moiety. Braz. J. Pharm. Sci. 2018, 54, e17281. [Google Scholar] [CrossRef] [Green Version]
- Shoman, M.E.; Abdel-Aziz, M.; Aly, O.M.; Farag, H.H.; Morsy, M.A. Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives. Eur. J. Med. Chem. 2009, 44, 3068–3076. [Google Scholar] [CrossRef] [PubMed]
- Abdelall, E.K.A.; Lamie, P.F.; Aboelnaga, L.S.; Hassan, R.M. Trimethoxyphenyl Containing Compounds: Synthesis, Biological Evaluation, Nitric Oxide Release, Modeling, Histochemical and Histopathological studies. Bioorg. Chem. 2022, 124, 105806. [Google Scholar] [CrossRef] [PubMed]
- Sava, A.; Buron, F.; Routier, S.; Panainte, A.; Bibire, N.; Profire, L. New Nitric Oxide-Releasing Indomethacin Derivatives with 1,3-Thiazolidine-4-one Scaffold: Design, Synthesis, In Silico and In Vitro Studies. Biomed. Pharm. 2021, 139, 111678. [Google Scholar] [CrossRef]
- Sava, A.; Buron, F.; Routier, S.; Panainte, A.; Bibire, N.; Constantin, S.M.; Lupascu, F.G.; Focsa, A.V.; Profire, L. Design, Synthesis, In Silico and In Vitro Studies for New Nitric Oxide-Releasing Indomethacin Derivatives with 1,3,4-oxadiazole-2-thiol Scaffold. Int. J. Mol. Sci. 2021, 22, 7079. [Google Scholar] [CrossRef]
- Sakr, A.; Rezq, S.; Ibrahim, S.M.; Soliman, E.; Baraka, M.M.; Romero, D.G.; Kothayer, H. Design and Synthesis of Novel Quinazolinones Conjugated Ibuprofen, Indole Acetamide, or Thioacetohydrazide as Selective COX-2 Inhibitors: Anti-Inflammatory, Analgesic and Anticancer Activities. J. Enzym. Inhib. Med. Chem. 2021, 36, 1810–1828. [Google Scholar] [CrossRef]
- Fadaly, W.A.A.; Elshaier, Y.A.M.M.; Hassanein, E.H.M.; Abdellatif, K.R.A. New 1,2,4-Triazole/Pyrazole Hybrids Linked to Oxime Moiety as Nitric Oxide Donor Celecoxib Analogs: Synthesis, Cyclooxygenase Inhibition Anti-Inflammatory, Ulcerogenicity, Anti-Proliferative Activities, Apoptosis, Molecular Modeling and Nitric Oxide Release Studies. Bioorg. Chem. 2020, 98, 103752. [Google Scholar]
- Nathan, C.; Xie, Q.W. Nitric Oxide Synthases: Roles, Tolls, and Controls. Cell 1994, 78, 915–918. [Google Scholar] [CrossRef]
- Moncada, S.; Palmer, R.M.; Higgs, E.A. Nitric oxide: Physiology, Pathophysiology, and Pharmacology. Pharm. Rev. 1991, 43, 109–142. [Google Scholar] [PubMed]
- John, P.; Cooke, M.; Victor, J.; Dzau, M. Nitric Oxide Synthase: Role in the Genesis of Vascular Disease. Annu. Rev. Med. 1997, 48, 489–509. [Google Scholar] [CrossRef] [Green Version]
- Ongini, E.; Bolla, M. Nitric-Oxide Based Nonsteroidal Anti-Inflammatory Agents. Drug. Discov. Today Strat. 2006, 3, 395. [Google Scholar] [CrossRef]
- Brown, J.F.; Hanson, P.J.; Whittle, B.J. Nitric Oxide Donors Increase Mucus Gel Thickness in Rat Stomach. Eur. J. Pharm. 1992, 223, 103–104. [Google Scholar] [CrossRef]
- Barrachina, M.D.; Calatayud, S.; Canet, A.; Bello, R.; Díaz de Rojas, F.; Guth, P.H.; Esplugues, J.V. Transdermal Nitroglycerin Prevents Nonsteroidal Anti-Inflammatory Drug Gastropathy. Eur. J. Pharm. 1995, 281, R3–R4. [Google Scholar] [CrossRef]
- Lanas, A.; Bajador, E.; Serrano, P.; Fuentes, J.; Carreño, S.; Guardia, J.; Sanz, M.; Montoro, M.; Sáinz, R. Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk Of Upper Gastrointestinal Bleeding. N. Engl. J. Med. 2000, 343, 834–839. [Google Scholar] [CrossRef]
- Huerta, S. Nitric Oxide for Cancer Therapy. Future Sci. OA 2015, 1, FSO44. [Google Scholar] [CrossRef] [Green Version]
- Hawkey, C.J.; Jones, J.I.; Atherton, C.T.; Skelly, M.M.; Bebb, J.R.; Fagerholm, U.; Jonzon, B.; Karlsson, P.; Bjarnason, I.T. Gastrointestinal Safety ff AZD3582, a Cyclooxygenase Inhibiting Nitric Oxide Donator: Proof of Concept Study in Humans. Gut 2003, 52, 1537–1542. [Google Scholar] [CrossRef]
- Geusens, P. Naproxcinod, a New Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD). Expert Opin. Biol. 2009, 9, 649–657. [Google Scholar] [CrossRef]
- Lolli, M.L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Coruzzi, G.; Manarini, S.; Fruttero, R.; Gasco, A. A New Class of Ibuprofen Derivatives with Reduced Gastrotoxicity. J. Med. Chem. 2001, 44, 3463–3468. [Google Scholar] [CrossRef]
- Bhardwaj, A.; Huang, Z.J.; Kaur, J.; Knaus, E.E. Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO2NHOH) Cyclooxygenase-2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Anti-inflammatory Agents. ChemMedChem 2012, 7, 62–67. [Google Scholar] [CrossRef] [PubMed]
- Huang, Z.; Velazquez, C.; Abdellatif, K.; Chowdhury, M.; Jain, S.; Reisz, J.; Dumond, J.; King, S.B.; Knaus, E. Acyclic Triaryl Olefins Possessing a Sulfohydroxamic Acid Pharmacophore: Synthesis, Nitric Oxide/Nitroxyl Release, Cyclooxygenase Inhibition, and Anti-Inflammatory Studies. Org. Biomol. Chem. 2010, 8, 4124–4130. [Google Scholar] [CrossRef] [PubMed]
- Elliott, S.N.; Wallace, J.L. Nitric Oxide: A Regulator of Mucosal Defense and Injury. J. Gastroenterol. 1998, 33, 792–803. [Google Scholar] [CrossRef] [PubMed]
- Biava, M.; Battilocchio, C.; Poce, G.; Alfonso, S.; Consalvi, S.; Di Capua, A.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; et al. Enhancing the Pharmacodynamic Profile of a Class of Selective Cox-2 Inhibiting Nitric Oxide Donors. Bioorg. Med. Chem. 2014, 22, 772–786. [Google Scholar] [CrossRef] [PubMed]
- Ren, S.Z.; Wang, Z.C.; Zhu, D.; Zhu, X.H.; Shen, F.Q.; Wu, S.Y.; Chen, J.J.; Xu, C.; Zhu, H.L. Design, Synthesis And Biological Evaluation of Novel Ferrocene-Pyrazole Derivatives Containing Nitric Oxide Donors as COX-2 Inhibitors for Cancer Therapy. Eur. J. Med. Chem. 2018, 157, 909–924. [Google Scholar] [CrossRef]
- Rabender, C.; Alam, A.; Mikkelsen, R. Ionizing Radiation Induced Nitric Oxide Signaling. Austin J. Nucl. Med. Radiother. 2014, 1, 5. [Google Scholar]
- Burney, S.; Caulfield, J.L.; Niles, J.C.; Wishnok, J.S.; Tannenbaum, S.R. The Chemistry of DNA Damage From Nitric Oxide and Peroxynitrite. Mutat. Res.-Fund. Mol. M 1999, 424, 37–49. [Google Scholar] [CrossRef]
- Folkes, L.K.; O’Neill, P. Modification of DNA damage mechanisms by nitric oxide during ionizing radiation. Free Radic. Biol. Med. 2013, 58, 14–25. [Google Scholar] [CrossRef]
- Bechmann, N.; Kniess, T.; Köckerling, M.; Pigorsch, A.; Steinbach, J.; Pietzsch, J. Novel (Pyrazolyl)Benzenesulfonamides with a Nitric Oxide-Releasing Moiety as Selective Cyclooxygenase-2 Inhibitors. Bioorg. Med. Chem. Lett. 2015, 25, 3295–3300. [Google Scholar] [CrossRef]
- Pietzsch, J.; Bechmann, N.; Hauser, S.; Hofheinz, F.; Kniess, T. Nitric Oxide-Releasing Selective Cyclooxygenase-2 Inhibitors as Promising Radiosensitizers in Melanoma Cells In Vitro: Supplemental Information. Ann. Radiat. Oncol. 2018, 1, 1010. [Google Scholar]
- Reza Massah, A.; Reza Momeni, A.; Dabagh, M.; Aliyan, H.; Javaherian Naghash, H. Facile Synthesis ofN–Acylsulfonamide in the Presence of Silica Chloride (SiO2-Cl) both under Heterogeneous and Solvent-Free Conditions. Synth. Commun. 2008, 38, 265–273. [Google Scholar] [CrossRef]
- Mohsin, N.-u.-A.; Irfan, M. Selective Cyclooxygenase-2 Inhibitors: A Review of Recent Chemical Scaffolds with Promising Anti-Inflammatory and COX-2 Inhibitory Activities. Med. Chem. Res. 2020, 29, 809–830. [Google Scholar] [CrossRef]
- Sharma, V.; Bhatia, P.; Alam, O.; Javed Naim, M.; Nawaz, F.; Ahmad Sheikh, A.; Jha, M. Recent Advancement in the Discovery and Development of COX-2 Inhibitors: Insight Into Biological Activities and SAR Studies (2008–2019). Bioorg. Chem. 2019, 89, 103007. [Google Scholar] [CrossRef] [PubMed]
- Carullo, G.; Galligano, F.; Aiello, F. Structure–Activity Relationships for the Synthesis of Selective Cyclooxygenase 2 Inhibitors: An Overview (2009–2016). MedChemComm 2017, 8, 492–500. [Google Scholar] [CrossRef]
- Laube, M.; Gassner, C.; Kniess, T.; Pietzsch, J. Synthesis and Cyclooxygenase Inhibition of Sulfonamide-Substituted (Dihydro)Pyrrolo[3,2,1-hi]indoles and Their Potential Prodrugs. Molecules 2019, 24, 3807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Talley, J.J.; Bertenshaw, S.R.; Brown, D.L.; Carter, J.S.; Graneto, M.J.; Kellogg, M.S.; Koboldt, C.M.; Yuan, J.; Zhang, Y.Y.; Seibert, K. N-[[(5-Methyl-3-Phenylisoxazol-4-Yl)-Phenyl]Sulfonyl]Propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. J. Med. Chem. 2000, 43, 1661–1663. [Google Scholar] [CrossRef] [PubMed]
- Qandil, A.M.; El Mohtadi, F.H.; Tashtoush, B.M. Chemical and In Vitro Enzymatic Stability of Newly Synthesized Celecoxib Lipophilic and Hydrophilic Amides. Int. J. Pharm. 2011, 416, 85–96. [Google Scholar] [CrossRef] [PubMed]
- Donovan, S.F.; Pescatore, M.C. Method for Measuring the Logarithm ff the Octanol-Water Partition Coefficient by Using Short Octadecyl-Poly(Vinyl Alcohol) High-Performance Liquid Chromatography Columns. J. Chromatogr. A 2002, 952, 47–61. [Google Scholar] [CrossRef]
- Seifert, V.; Richter, S.; Bechmann, N.; Bachmann, M.; Ziegler, C.G.; Pietzsch, J.; Ullrich, M. HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance In Pheochromocytoma: Insights from 3D Models. Cancers 2021, 13, 385. [Google Scholar] [CrossRef] [PubMed]
- Xue, X.; Shah, Y.M. Hypoxia-Inducible Factor-2α Is Essential in Activating The COX2/Mpges-1/PGE 2 Signaling Axis in Colon Cancer. Carcinogenesis 2013, 34, 163–169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, C.-X.; Luo, C.-L.; Wu, X.-H. Hypoxia Promotes 786-O Cells Invasiveness and Resistance to Sorafenib Via HIF-2α/COX-2. Med. Oncol. 2015, 32, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Gudkov, S.V.; Shilyagina, N.Y.; Vodeneev, V.A.; Zvyagin, A.V. Targeted Radionuclide Therapy of Human Tumors. Int. J. Mol. Sci. 2016, 17, 33. [Google Scholar] [CrossRef] [PubMed]
- Ersahin, D.; Doddamane, I.; Cheng, D. Targeted Radionuclide Therapy. Cancers 2011, 3, 3838–3855. [Google Scholar] [CrossRef]
- Mak, I.Y.F.; Hayes, A.R.; Khoo, B.; Grossman, A. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma. Neuroendocrinology 2019, 109, 287–298. [Google Scholar] [CrossRef]
- Tai, M.-H.; Weng, C.-H.; Mon, D.-P.; Hu, C.-Y.; Wu, M.-H. Ultraviolet C Irradiation Induces Different Expression of Cyclooxygenase 2 In NIH 3T3 Cells and A431 Cells: The Roles of COX-2 Are Different in Various Cell Lines. Int. J. Mol. Sci. 2012, 13, 4351–4366. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allen, C.P.; Tinganelli, W.; Sharma, N.; Nie, J.; Sicard, C.; Natale, F.; King III, M.; Keysar, S.B.; Jimeno, A.; Furusawa, Y. DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation. Front. Oncol. 2015, 5, 260. [Google Scholar] [CrossRef] [Green Version]
- Suzuki, K.; Gerelchuluun, A.; Hong, Z.; Sun, L.; Zenkoh, J.; Moritake, T.; Tsuboi, K. Celecoxib Enhances Radiosensitivity of Hypoxic Glioblastoma Cells Through Endoplasmic Reticulum Stress. Neuro. Oncol. 2013, 15, 1186–1199. [Google Scholar] [CrossRef]
- Zhang, S.X.; Qiu, Q.H.; Chen, W.B.; Liang, C.H.; Huang, B. Celecoxib Enhances Radiosensitivity Via Induction of G(2)-M Phase Arrest and Apoptosis in Nasopharyngeal Carcinoma. Cell. Physiol. Biochem. 2014, 33, 1484–1497. [Google Scholar] [CrossRef]
- Niu, K.; Chen, X.W.; Qin, Y.; Zhang, L.P.; Liao, R.X.; Sun, J.G. Celecoxib Blocks Vasculogenic Mimicry via an Off-Target Effect to Radiosensitize Lung Cancer Cells: An Experimental Study. Front. Oncol. 2021, 11, 697227. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.-T.; Hu, W.-T.; Zhou, J.-Y.; Tu, Y. Celecoxib Enhances the Radiosensitivity of HCT116 Cells in a COX-2 Independent Manner By Up-Regulating BCCIP. Am. J. Transl. Res. 2017, 9, 1088–1100. [Google Scholar]
- Hosseinimehr, S.J.; Fathi, M.; Ghasemi, A.; Shiadeh, S.N.R.; Pourfallah, T.A. Celecoxib Mitigates Genotoxicity Induced by Ionizing Radiation in Human Blood Lymphocytes. Res. Pharm. Sci. 2017, 12, 82–87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laube, M.; Kniess, T.; Pietzsch, J. Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy—A Hypothesis-Driven Review. Antioxidants 2016, 5, 14. [Google Scholar] [CrossRef] [Green Version]
- Azmoonfar, R.; Amini, P.; Saffar, H.; Motevaseli, E.; Khodamoradi, E.; Shabeeb, D.; Musa, A.E.; Najafi, M. Celecoxib A Selective COX-2 Inhibitor Mitigates Fibrosis but not Pneumonitis Following Lung Irradiation: A Histopathological Study. Curr. Drug. 2020, 15, 351–357. [Google Scholar] [CrossRef]
- Lalla, R.V.; Choquette, L.E.; Curley, K.F.; Dowsett, R.J.; Feinn, R.S.; Hegde, U.P.; Pilbeam, C.C.; Salner, A.L.; Sonis, S.T.; Peterson, D.E. Randomized Double-Blind Placebo-Controlled Trial of Celecoxib for Oral Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer. Oral. Oncol. 2014, 50, 1098–1103. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Yue, J.B.; Liu, J.; Sun, X.D.; Hu, X.D.; Sun, J.J.; Li, Y.H.; Yu, J.M. Effect of Celecoxib on Inhibiting Tumor Repopulation During Radiotherapy in Human Fadu Squamous Cell Carcinoma. Contemp. Oncol. 2014, 18, 260–267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pietzsch, J.; Laube, M.; Bechmann, N.; Pietzsch, F.J.; Kniess, T. Protective Effects ff 2,3-Diaryl-Substituted Indole-Based Cyclooxygenase-2 Inhibitors on Oxidative Modification of Human Low Density Lipoproteins In Vitro. Clin. Hemor. Microcirc. 2015, 61, 615–632. [Google Scholar] [CrossRef]
- Frankenberg-Schwager, M. Review of Repair Kinetics for DNA Damage Induced in Eukaryotic Cells In Vitro By Ionizing Radiation. Radiother. Oncol. 1989, 14, 307–320. [Google Scholar] [CrossRef]
- Hosseinimehr, S.J. Trends in the Development of Radioprotective Agents. Drug. Discov. Today 2007, 12, 794–805. [Google Scholar] [CrossRef]
- Pedersen, D.S.; Rosenbohm, C. Dry Column Vacuum Chromatography. Synthesis 2001, 2001, 2431–2434. [Google Scholar] [CrossRef]
- Uddin, M.J.; Crews, B.C.; Ghebreselasie, K.; Huda, I.; Kingsley, P.J.; Ansari, M.S.; Tantawy, M.N.; Reese, J.J.; Marnett, L.J. Fluorinated Cyclooxygenase-2 Inhibitors as Agents in PET Imaging of Inflammation and Cancer. Cancer Prev. Res. 2011, 4, 1536–1545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gassner, C.; Neuber, C.; Laube, M.; Bergmann, R.; Kniess, T.; Pietzsch, J. Development of a 18F-labeled Diaryl-Substituted Dihydropyrrolo[3,2,1-hi]indole as Potential Probe for Functional Imaging of Cyclooxygenase-2 with PET. ChemistrySelect 2016, 1, 5812–5820. [Google Scholar] [CrossRef]
- Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M.H.; Reynolds, D.P. Fast Gradient HPLC Method to Determine Compounds Binding to Human Serum Albumin. Relationships with Octanol/Water and Immobilized Artificial Membrane Lipophilicity. J. Pharm. Sci. 2003, 92, 2236–2248. [Google Scholar] [CrossRef]
- Seifert, V.; Liers, J.; Kniess, T.; Richter, S.; Bechmann, N.; Feldmann, A.; Bachmann, M.; Eisenhofer, G.; Pietzsch, J.; Ullrich, M. Fluorescent Mouse Pheochromocytoma Spheroids Expressing Hypoxia-Inducible Factor 2 Alpha: Morphologic and Radiopharmacologic Characterization. J. Cell. Biotechnol. 2019, 5, 135–151. [Google Scholar] [CrossRef]
- Rothe, R.; Schulze, S.; Neuber, C.; Hauser, S.; Rammelt, S.; Pietzsch, J. Adjuvant Drug-Assisted Bone Healing: Part I – Modulation of Inflammation. Clin. Hemorheol. Microcirc. 2019, 73, 381–408. [Google Scholar] [CrossRef] [PubMed]
R1 | R2 | R3 | R4 | IC50 (COX-1) [µM] | IC50 (COX-2) [µM] | SI | LogD7.4 | |
---|---|---|---|---|---|---|---|---|
4a * | CH3 | NH2 | Cl | Cl | >100 | 0.22 | >454 | 3.61 |
4b | OCH3 | NH2 | Cl | Cl | 0.297 | 0.127 | 2.3 | 3.53 |
4c | CH3 | CH3 | Cl | Cl | >100 | 0.72 | >138 | 3.90 |
4d | OCH3 | CH3 | Cl | Cl | >100 | 0.480 | >208 | 3.84 |
4e * | CH3 | NH2 | H | Cl | >100 | 1.27 | >78 | 3.14 |
4f | OCH3 | NH2 | H | Cl | >100 | 0.37 | >270 | 3.06 |
5a * | CH3 | NH2 | Cl | ONO2 | 61.0 | 0.28 | >217 | 3.76 |
5b | OCH3 | NH2 | Cl | ONO2 | 2.573 | 0.434 | 5.9 | 3.67 |
5c | CH3 | CH3 | Cl | ONO2 | >100 | 2.120 | >47 | 4.04 |
5d | OCH3 | CH3 | Cl | ONO2 | >100 | 1.082 | >92 | 4.02 |
5e * | CH3 | NH2 | H | ONO2 | >100 | 0.89 | >112 | 3.40 |
5f | OCH3 | NH2 | H | ONO2 | >100 | 1.18 | >84 | 3.32 |
6a ** | CH3 | NHCOEt | Cl | ONO2 | >100 | >100 | - | 2.27 |
6b ** | OCH3 | NHCOEt | Cl | ONO2 | ~100 | >100 | - | 2.10 |
6c ** | CH3 | NHCOEt | H | ONO2 | >100 | >100 | - | 1.82 |
6d ** | OCH3 | NHCOEt | H | ONO2 | >100 | >100 | - | 1.55 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brandt, F.; Ullrich, M.; Seifert, V.; Haase-Kohn, C.; Richter, S.; Kniess, T.; Pietzsch, J.; Laube, M. Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells. Molecules 2022, 27, 6587. https://doi.org/10.3390/molecules27196587
Brandt F, Ullrich M, Seifert V, Haase-Kohn C, Richter S, Kniess T, Pietzsch J, Laube M. Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells. Molecules. 2022; 27(19):6587. https://doi.org/10.3390/molecules27196587
Chicago/Turabian StyleBrandt, Florian, Martin Ullrich, Verena Seifert, Cathleen Haase-Kohn, Susan Richter, Torsten Kniess, Jens Pietzsch, and Markus Laube. 2022. "Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells" Molecules 27, no. 19: 6587. https://doi.org/10.3390/molecules27196587